In a Phase II basket study (STARTRK-2), the therapeutic effects of entrectinib were evaluated in patients suffering from different tumors, and the only glioma patient with BCAN-NTRK1 fusion represented almost a halving in tumor volume (41). The gene discussed is NTRK1; the disease is glioma.